An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Methenmadinone caproate (MMC, also known as superlutin caproate) is a progestin medication which was developed in Czechoslovakia in the 1960s and was studied for potential use in combined injectable contraceptives in the 1970s but was never marketed. It was studied as a combined injectable contraceptive in combination with estradiol valerate at doses of 60 mg and 10 mg, respectively, once a month by intramuscular injection (tentative brand name Lutofollin). MMC is the C17α caproate (hexanoate) ester of methenmadinone and an analogue of methenmadinone acetate (MMA; superlutin). In addition to MMA, analogues of MMC include chlormadinone caproate, gestonorone caproate, hydroxyprogesterone caproate, medroxyprogesterone caproate, and megestrol caproate.

Property Value
dbo:abstract
  • Methenmadinone caproate (MMC, also known as superlutin caproate) is a progestin medication which was developed in Czechoslovakia in the 1960s and was studied for potential use in combined injectable contraceptives in the 1970s but was never marketed. It was studied as a combined injectable contraceptive in combination with estradiol valerate at doses of 60 mg and 10 mg, respectively, once a month by intramuscular injection (tentative brand name Lutofollin). MMC is the C17α caproate (hexanoate) ester of methenmadinone and an analogue of methenmadinone acetate (MMA; superlutin). In addition to MMA, analogues of MMC include chlormadinone caproate, gestonorone caproate, hydroxyprogesterone caproate, medroxyprogesterone caproate, and megestrol caproate. (en)
dbo:casNumber
  • 6723-94-0
dbo:class
dbo:fdaUniiCode
  • T7YQK45FEA
dbo:thumbnail
dbo:wikiPageID
  • 58503126 (xsd:integer)
dbo:wikiPageLength
  • 5556 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1108883969 (xsd:integer)
dbo:wikiPageWikiLink
dbp:c
  • 28 (xsd:integer)
dbp:casNumber
  • 6723 (xsd:integer)
dbp:class
dbp:h
  • 38 (xsd:integer)
dbp:iupacName
  • [-17-Acetyl-10,13-dimethyl-16-methylene-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate (en)
dbp:o
  • 4 (xsd:integer)
dbp:routesOfAdministration
dbp:smiles
  • O[C@@]1CC[C@]2[C@@]3C=CC4=CC=O (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • WQBCIYORLVRAQX-BDPSOKNUSA-N (en)
dbp:synonyms
  • MMC; Superlutin caproate; Methenmadinone hexanoate; Lutofollin; 17α-Hydroxy-16-methyl-6-dehydroprogesterone caproate; 17α-Hydroxy-16-methylpregna-4,6-diene-3,20-dione 17α-hexanoate (en)
dbp:unii
  • T7YQK45FEA (en)
dbp:width
  • 250 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Methenmadinone caproate (MMC, also known as superlutin caproate) is a progestin medication which was developed in Czechoslovakia in the 1960s and was studied for potential use in combined injectable contraceptives in the 1970s but was never marketed. It was studied as a combined injectable contraceptive in combination with estradiol valerate at doses of 60 mg and 10 mg, respectively, once a month by intramuscular injection (tentative brand name Lutofollin). MMC is the C17α caproate (hexanoate) ester of methenmadinone and an analogue of methenmadinone acetate (MMA; superlutin). In addition to MMA, analogues of MMC include chlormadinone caproate, gestonorone caproate, hydroxyprogesterone caproate, medroxyprogesterone caproate, and megestrol caproate. (en)
rdfs:label
  • Methenmadinone caproate (en)
owl:differentFrom
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is dbp:caption of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License